Message from the Collection Editors

Human coronaviruses (HCoVs), including NL63, 229E, OC43, and HKU1, are responsible for seasonal mild respiratory illness. However, two HCoVs (SARS and MERS) have been shown to cause severe morbidity and mortality in humans. Recently (December 2019) a novel HCoV, Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2), was identified in the city of Wuhan in China, and has been responsible for the COVID-19 pandemic with an alarming case fatality, posing an unprecedented threat to human health and economy. To date, no United States Food and Drug Administration (FDA)-approved vaccines and/or specific antivirals are available for the treatment of SARS-CoV-2 infection in humans, which has triggered vast scientific efforts to develop countermeasures to deal with SARS-CoV-2 infection.

In this Topical Collection about coronavirus, we aim to cover all the aspects related to coronavirus disease, including virus–host interactions, viral pathogenesis, animal models, antivirals, vaccine development, immunity, prophylactics, therapeutics, and reverse genetics.
Editor-in-Chief

Dr. Eric O. Freed
Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

**Journal Rank:** JCR - Q2 (*Virology*) / CiteScore - Q1 (Infectious Diseases)

Contact Us

*Viruses* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

viruses@mdpi.com
@VirusesMDPI